Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890598 · ClinicalTrials.gov registry record · Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT06890598 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 700 participants, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06890598, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Durvalumab
- DRUG Olomorasib
Study Locations (20)
Florida
- Boca Raton Regional Hospital - Boca Raton
- Florida Cancer Specialists - South - Fort Myers
- University of Florida - Jacksonville - Jacksonville
- Miami Cancer Institute at Baptist Health, Inc. - Miami
- Florida Cancer Specialists North - St. Petersburg
- Comprehensive Hematology Oncology - St. Petersburg
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists East - West Palm Beach
California
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- Profound Research LLC - Oceanside
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
- Stanford Cancer Center - Palo Alto
- Kaiser Permanente San Diego Mission Road - San Diego
- BASS Cancer Center - Walnut Creek
Alabama
- Clearview Cancer Institute - Huntsville
- Infirmary Cancer Care - Mobile
Arizona
- The University of Arizona Cancer Center - North Campus - Tucson
Arkansas
- Highlands Oncology Group - Springdale
Connecticut
- Hartford Hospital (HH) - Hartford
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2032-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06890598
The ClinicalTrials.gov registry entry for NCT06890598 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (120% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT06890598 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06890598 about?
NCT06890598 is a clinical study titled "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer". The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective tha...
What is the current status of trial NCT06890598?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2025-03-27. Estimated completion is 2032-02.
What conditions does trial NCT06890598 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06890598?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Durvalumab (DRUG), Olomorasib (DRUG).
Who is sponsoring clinical trial NCT06890598?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06890598 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.